Dave & Buster’s Stock Is Rising: What’s Going On?

Dave & Buster's Entertainment Inc (NASDAQ: PLAY) shares are trading higher Wednesday after the company reported first-quarter financial results</

Dave & Buster’s Entertainment Inc (NASDAQ:PLAY) shares are trading higher Wednesday after the company reported first-quarter financial results.

  • Q1 Revenue: $597.3 million missed estimates of $601.71 million
  • Q1 EPS: $1.45 beat estimates of $1.24

Revenue was up 32.4% year-over-year, while comparable store sales climbed 4.1%. 

The company said it signed two international franchise agreements for up to 15 stores in India and up to 5 stores in Australia.

Dave & Buster’s said it repurchased 3.6 million shares during the first quarter and ended the period with $581.7 million in liquidity, which included $91.5 million in cash. 

“Our extremely talented team of operators and support center employees continue to execute on the breadth of strategic opportunities we’ve identified to unlock significant revenue growth and cost efficiency opportunities in our business which will continue to bring meaningful upside to all stakeholders and in all macro-economic environments,” said Chris Morris, CEO of Dave & Buster’s.

Dave & Buster’s said it continues to focus on optimizing its business model to drive revenue and create cost savings across the company. It also plans 

Following the print, BMO Capital analyst Andrew Strelzik maintained Dave & Buster’s with an Outperform and raised the price target from $55 to $60.

See Also: These Analysts Revise Their Forecasts On J M Smucker After Q4 Results

PLAY Price Action: Dave & Buster’s shares were up 23.8% at $41.77 at the time of writing, according to Benzinga Pro.

Photo: Raila Spindola Raila from Pixabay.

Total
0
Shares
Related Posts
Read More

Canadian CBD-Focused Pharma Co. Gets Green Light To Produce Medical Marijuana In Brazil

Canada's MediPharm Labs has received a GMP certification from the Brazilian governing body, ANVISA. The approval allows for the production of active pharmaceutical ingredients (APIs) and end products for the Brazilian medical cannabis market. MediPharm has already received GMP certifications from the US FDA, the European Union, and Australia's TGA, and holds a drug establishment license from Health Canada. The Brazilian medical cannabis market is projected to reach CAD380m (USD282m) by 2025, according to industry forecasts. MediPharm Labs, which already produces two medical cannabis products with full ANVISA authorization for the Brazilian market, is potentially set for further product authorizations through the regulatory body, according to reports.

MEDIF